Top Industry Leaders in the Neurosyphilis Market
Latest Neurosyphilis Companies Update
Positive Phase 2b results for AL101 (Alopexx Pharmaceuticals) December 2023 breakthrough demonstrated AL101's potential as a safe and effective treatment for neurosyphilis, a previously unmet medical need. Phase 3 trials are expected to begin soon.
Focus on repurposing existing drugs Companies are exploring the efficacy of existing medications like minocycline and ceftriaxone for treating neurosyphilis, potentially offering faster treatment options while awaiting new drug approvals.
Luminex Corporation: November 2023, Luminex launched a multiplex assay called Verیده (Veride) for simultaneous detection of syphilis and other sexually transmitted infections, including HIV-1 and -2. This could potentially facilitate faster and more comprehensive diagnosis of neurosyphilis.
Mologic company is developing a rapid point-of-care test for syphilis, including neurosyphilis. While still in the early stages of development, such a test could significantly improve access to timely diagnosis in resource-limited settings.
List of Neurosyphilis Key Companies in the Market
- Abbott (US)
- Bayer AG (Germany)
- Eli Lilly and Company (US)
- GlaxoSmithKline plc. (UK)
- Novartis AG (Switzerland)
- Pfizer Inc. (US)
- Sanofi (France)